STOCKHOLM, SWEDEN / RankWire.AI / – The 2026 Nobel Prize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for their groundbreaking work that led to the creation of optogenetics. The Nobel Assembly at Karolinska Institutet announced the honor on October 5. Their research demonstrated how light-sensitive proteins can precisely modulate nerve cell activity, providing scientists a powerful tool to explore how specific brain circuits influence behavior, memory, and emotion.
Hegemann and Nagel identified channelrhodopsin, a protein in the single-celled alga Chlamydomonas that responds to blue light by opening a channel allowing charged ions into the cell, generating an electrical signal. They proved that cells expressing channelrhodopsin could be made sensitive to light, a crucial step toward transforming it into a biological switch. Their discovery linked a fundamental biological response to a versatile tool adaptable for various cell types.
Deisseroth advanced this discovery into the realm of neuroscience. He inserted the gene coding for channelrhodopsin into rat nerve cells and used blue light to activate nerve signals, publishing his breakthrough in 2005. By 2007, his team demonstrated that this light-controlled switch could operate within the brains of living mice. These developments established optogenetics as a practical method for precisely controlling neural circuits in living organisms.
From algal protein to a revolutionary neuroscience technique
Optogenetics merges genetic targeting with light stimulation to activate or inhibit specific cells. Researchers employ it to investigate the roles of targeted nerve-cell groups during particular behaviors or brain activities. The Nobel Assembly at Karolinska Institutet stated that this approach has transformed how scientists explore the living brain. Laboratories around the world now utilize optogenetics to map circuits involved in movement, learning, memory, emotion, and other functions. This method also enables researchers to link cellular changes to observable effects in live animals.
Furthermore, optogenetics has been instrumental in studying neurological and psychiatric disorders, including Parkinson’s disease, epilepsy, depression, and addiction. Clinical trials are underway exploring therapies like restoring vision in individuals with severe visual impairments. Although such medical applications remain experimental, the method’s principal impact lies in neuroscience research, allowing detailed examination of specific pathways through controlled light stimulation.
Three scientists share the 2026 Nobel in Medicine
Deisseroth is a Stanford University professor and investigator at the Howard Hughes Medical Institute in the United States. Hegemann conducts research at Humboldt University of Berlin, while Nagel is affiliated with the University of Würzburg in Germany. The trio will split the 12 million Swedish kronor prize. The medicine award marked the beginning of the 2026 Nobel announcements, which will also include prizes in physics, chemistry, literature, peace, and economic sciences. Each winner’s contribution represented a vital step in the evolution of modern optogenetics.
This Nobel recognizes a sequence of discoveries linking basic biological research in algae to a widely used tool in contemporary neuroscience. Channelrhodopsin provided the light-sensitive molecular switch, with subsequent work adapting it for precise control over nerve cells. Today, optogenetics is employed across neuroscience and other biological fields. The laureates will receive their Nobel medals and diplomas at the Stockholm ceremony on December 10, coinciding with the anniversary of Alfred Nobel’s death and following longstanding tradition.